advertisement
Biogen Idec initiated with "buy"
03/09/10 - Soleil Securities Group
NEW YORK, March 9 (newratings.com) - Analysts at Soleil Securities Group initiate coverage of Biogen Idec Inc (BIIB) with a "buy" rating. The target price is set to $70.
News